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Abstract
Background: We have previously developed a long RT-PCR method for selective amplification of full-length PKD1
transcripts (13.6 kb) and a long-range PCR for amplification in the reiterated region (18 kb) covering exons 14 and 34 of
the PKD1 gene. These have provided us with an opportunity to study PKD1 mutations especially in its reiterated region
which is difficult to examine. In this report, we have further developed the method of multiple restriction fragment-single
strand conformation polymorphism (MRF-SSCP) for analysis of PKD1 mutations in the patients with autosomal dominant
polycystic kidney disease (ADPKD). Novel and de novo PKD1 mutations are identified and reported.
Methods: Full-length PKD1 cDNA isolated from the patients with ADPKD was fractionated into nine overlapping
segments by nested-PCR. Each segment was digested with sets of combined restriction endonucleases before the SSCP
analysis. The fragments with aberrant migration were mapped, isolated, and sequenced. The presence of mutation was
confirmed by the long-range genomic DNA amplification in the PKD1 region, sequencing, direct mutation detection, and
segregation analysis in the affected family.
Results: Five PKD1 mutations identified are two frameshift mutations caused by two di-nucleotide (c. 5225_5226delAG
and c.9451_9452delAT) deletions, a nonsense (Q1828X, c.5693C>T) mutation, a splicing defect attributable to 31
nucleotide deletion (g.33184_33214del31), and an in-frame deletion (L3287del, c.10070_10072delCTC). All mutations
occurred within the reiterated region of the gene involving exons 15, 26, 15, 19 and 29, respectively. Three mutations
(one frameshift, splicing defect, and in-frame deletion) are novel and two (one frameshift and nonsense) known. In
addition, two mutations (nonsense and splicing defect) are possibly de novo.
Conclusion: The MRF-SSCP method has been developed to analyze PCR products generated by the long RT-PCR and
nested-PCR technique for screening PKD1 mutations in the full-length cDNA. Five mutations identified were all in the
reiterated region of this gene, three of which were novel. The presence of de novo PKD1 mutations indicates that this
gene is prone to mutations.
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Background
Autosomal dominant polycystic kidney disease (ADPKD;
MIM# 173900) is a potentially fatal disease and one of the
most common inherited disorders in humans, affecting
approximately 1 per 1,000 individuals. The characteristic
abnormality is the presence of multiple fluid-filled cysts
in both kidneys causing defective functions, ultimately
leading to end stage renal disease (ESRD) [1]. Liver cysts
and other extra-renal manifestations such as cerebral
aneurysm and mitral valve defect, can also be observed
[2]. Two known genes are responsible for this disease:
PKD1 (MIM# 601313) at 16p13.3 [3-6] and PKD2 (MIM#
173910) at 4q21-23 [7]. The presence of the third locus
responsible for this disease is still controversial [8,9]. A
majority of cases (85%) is caused by mutations in PKD1.
PKD1 gene spans >50 kb of genomic DNA, containing 46
exons and transcribing ~14-kb mRNA [3-6] that encodes
a large membrane-associated glycoprotein, polycystin-1,
comprising 4,302 amino acids. The protein possibly par-
ticipates in the signal-transduction pathway by coordinat-
ing with polycystin-2, the product of PKD2, in mediating
mechanosensory calcium mobilization by function as
flow-sensitive mechanosensors in the primary cilium of
renal epithelium [10]. A failure of fluid-flow sensation of
the cells may disturb tissue morphogenesis, triggering
abnormal cell proliferation and cyst formation. Renal
cysts are likely to develop after a second-hit or somatic
mutation, which inactivates the inherited normal allele of
the same locus, or occasionally an allele of another coun-
terpart locus (i.e.PKD2 or vice versa), giving rise to a trans-
heterozygous event [11].
To date, at least 250 unique PKD1 mutations have been
identified as listed in the Human Gene Mutation Data-
base (HGMD, http://uwcmml1s.uwcm.ac.uk/uwcm/mg/
search/120293.html) [12] and also reported more
recently [13-15]. Three-fourths of mutations in this gene
result in truncated protein products, suggesting its inacti-
vation or loss-of-function mechanism. Most previous
studies have found unclear genotype-phenotype correla-
tions for PKD1 mutations. However, a recent report has
shown the significant correlation between the position of
mutation and disease severity (more severe in more 5'
mutation), raising the questions whether PKD1 mutations
simply inactivate all products of the gene [16]. Mutation
databases from worldwide population and additional
experiments would be useful to unravel the precise mech-
anism by which PKD1  mutations cause diverse
phenotypes.
Analysis of PKD1 mutations is labor-intensive, time-con-
suming, and expensive because of its large size, the pres-
ence of a very high GC content, and most severely the
presence of more than six homologous genes, which are
highly homologous to the 5' region (exons 1–33) of PKD1
[4,17]. The latter has made mutation detection in this
gene much more difficult. The methods successfully
developed for mutation analysis of this gene are based on
discrimination of PKD1 from the non-functional homol-
ogous genes, by enrichment of PKD1 sequence while sup-
pressing the homologous ones to undetectable levels.
PKD1 mutations occur throughout the gene with appar-
ently no mutational "hot-spots", rendering characteriza-
tion of all disease causing PKD1  mutations in various
ethnic groups essential for comprehension of molecular
mechanism of the disease and for providing diagnostic
genetic testing. Our group aim to fulfill PKD1-mutation
database of Thai patients and have previously developed
a long RT-PCR technique for isolation of the entire coding
sequence of PKD1 (~13 kb) for the analysis of its muta-
tions without interference from the homologous
sequences [18]. The analysis of PKD1 transcript provides
an opportunity for ex vivo study of splicing defects prior to
identification of causative mutations. In addition, a long-
range PCR (LR-PCR) for amplification of PKD1-specific
genomic sequence with the length of about 18 kb in the
reiterated region covering exons 14–33 has also been
established for further analysis of PKD1 [19]. Using these
techniques, we have previously identified and reported
two mutations causing splicing defects of PKD1  tran-
scripts in Thai families with ADPKD [19,20].
To increase efficiency of screening and identification for
other types of mutations in the reiterated region of PKD1,
we have further developed a multiple restriction frag-
ment-single strand conformation polymorphism (MRF-
SSCP) method [21], in addition to the long RT-PCR and
LR-PCR techniques. Since the SSCP method is more effi-
cient for screening mutation in a short fragment (less than
300 bp), we used different sets of restriction endonucle-
ases for digestions of each PKD1-cDNA segment so that
the entire segment was efficiently screened. We have
applied this procedure for screening and identifying PKD1
mutations in Thai patients with ADPKD. Here, we report
three novel and two recurrent mutations of PKD1 identi-
fied in Thai patients; two mutations are possibly de novo.
Methods
ADPKD families and linkage study
Ten unrelated Thai families with ADPKD attending our
clinics at Divisions of Medical Genetics and Nephrology,
Department of Medicine, Faculty of Medicine Siriraj Hos-
pital, Bangkok, were included in this study. ADPKD was
diagnosed according to established clinical and genetic
criteria [22]. Research investigation was conducted in
accordance with the Faculty of Medicine Siriraj Hospital
Ethics Committee's guidelines and in accordance with the
Helsinki Declaration. Blood samples were collected after
informed consent for RNA and DNA preparations. Link-BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
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age analysis was performed by using 5 polymorphic DNA
markers on chromosome 16p including D16S85 (3'
HVR), SM7, 16AC2.5, SM6, and KG8 as previously
described [19].
Full-length PKD1 cDNA amplification by long RT-PCR
RNA prepared from fresh blood sample was used for full-
length PKD1 cDNA (~13 kb) amplification by long RT-
PCR. The full-length cDNA was then fractionated into
nine overlapping fragments by nested-PCR methods as
previously described [18]. The sizes of nested-PCR frag-
ments were 1,473–1,678 bp (Table 1 and Figure 1A). The
product with abnormal size as shown by agarose gel elec-
trophoresis was further analyzed by restriction endonucle-
ase mapping and sequencing to directly identify abnormal
RNA splicing.
Screening of PKD1 mutation by MRF-SSCP
The nested-PCR fragments from PKD1 cDNA showing no
abnormality in size were further screened for mutation by
a multiple restriction fragment-single strand conforma-
tion polymorphism (MRF-SSCP) method. This method
firstly developed by Lee et al. [21] was modified to use sil-
ver staining instead of radioactive detection. A relatively
large PCR-product (1–2 kb) for SSCP method could be
analyzed since it was fractionated into several short frag-
ments by combined digestions with restriction endonu-
cleases. The restriction enzymes were selected by
consideration of their restriction maps on the sequences
so that each digestion produced 6–7 fragments with the
average size about 200–300 bp and resulted in a discrete
size distribution on the SSCP gel. Each nested-PCR frag-
ment was digested with at least two sets of combined
restriction endonucleases to generate overlapping-
digested products, in order to approximate the position of
Table 1: PCR primers and conditions for amplifications of PKD1 cDNA and DNA
Primer Primer Sequence (5'->3') Nucleotide 
Position
Location in 
PKD1 Transcript
PCR Product 
Size (bp)
Annealing 
Temperature 
(°C)
Mg2+ Conc. 
(mM)
cDNA amplification
TH1F CTGGGGACGGCGGGGCCATGCG 175–196a 5' UTR 13,634 68 1.2
TH1B GGCCTGGGGCAAGGGAGGATGACAA 13808–13784a 3' UTR
SI1F ACGGCGGGGCCATGCGCGCGCTGCCCTAAC 181–210a 5'UTR 1,554 72 3.0
SI1B CAGTGCTCGGCTGTGGCTGGGTGTGGCTCC 1734–1705a Exon 7
SI2F AGGAGCCTAGACGTGTGGATCG 1595–1616a Exon 6–7 1,678 65 1.5
SI2B CCTGCATCCTGTTCATCCGCTC 3272–3251a Exon 13
SI3F CATCAACGACAAGCAGTCCCT 3115–3135a Exon 12 1,575 60 1.5
SI3B CCACGGCCCACAGCAGAGAA 4689–4670a Exon 15
SI4F ATCTCTGCTGCCAATGACTCAG 4562–4583a Exon 15 1,473 60 1.5
SI4B GGGGAAGCTGTGGGAGAAAC 6034–6015a Exon 15
SI5F TCAATGCCTCCAACGCAGTCAGC 5808–5830a Exon 15 1,663 65 1.5
SI5B GTCTCATCCAGCACCAGCGTCTTG 7470–7447a Exon 18
SI6F AGCAGCGGCTCCAAGCGAG 7400–7418a Exon 17 1,506 65 3.0
SI6R CACAACGGAGTTGGCGGAGT 8905–8886a Exon 23
SI7F CCTTTCCCTTTGGCTATATCAG 8709–8730a Exon 23 1,518 60 1.5
SI7B CCAGGTAGACGGGATAGACAAC 10226–10205a Exon 30
SI8F GCCACCTGCTGCGTTCTCCT 10052–10071a Exon 29 1,539 65 1.5
SI8B CGTCCCCGAGCCATTGTGAG 11590–11571a Exon 40
SI9F CTTCAGCACCAGCGATTACGACGTT 11533–11557a Exon 40 1,650 65 1.5
SI9B AGAAAGTAATACTGAGCGGTGTCCACTC 13182–13155a 3' UTR
Genomic DNA amplification
SI3.1F GCAACGTCACCGTGAACTACAACGTAACCG 26340–26369b Exon 13 18,099 61 1.0
Ex34B GAGCAGGTCCGTTTCCATGTGGGTGTCTTG 44438–44409b Exon 34
SI4.2F CTTCCCCACCAACCACACGGTACAGC 29064–29039 Exon 15 486 62 1.0
SI4.2B AGGCCACTCACAGGCACCTGCACATC' 29523–29498 Exon 15
SI4.1F AGCCAACGCCACCGTGGAA 29476–29494b Exon 15 372 60 1.5
SI4.1B GCAGCCAGCAGGATCTGAAAATG 29847–29825 b Exon 15
SI6.1F CGCTGTGCACGCCCTCACCACCAAGGT 32835–32861 b Exon 18 480 60 1.5
SI6.1B GTGCAGCCAGACTGTGAGCCCCGTTGC 33314–33288 b Exon 20
SI7.2F GGAGTTACCATCTGAACCTCTCCAG 38978–39002 b Exon 25 698 60 1.0
SI7.2B CAGGATGAACACACGAGCCCTTCACAC 39675–39649 b IVS 26
SI8L TTCTTTGACAAGCACATCTGGC 41600–41579 Exon 29 336 57 1.0
SI7B CCAGGTAGACGGGATAGACAAC 41915–41894 Exon 30
aThe nucleotide positions are according to HUMPKD1A, GenBank Accession No. L33243. bThe nucleotide positions are according to 
HUMPKD1GEN, GenBank Accession No. L39891. Bold faces are primers for long-range PCR of which products were used as PKD1-specific 
templates for nested PCRs.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
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mutation in the shifted fragment on the SSCP gel (Table
2).
The digestion of nested-PCR fragments was performed in
a final volume of 25 µl, containing 10 µl of DNA, 2.5 µl
of 10× buffer, and 2–5 units of enzymes (e.g. Ava II + Hinf
I or Bgl I + Hha I), in the presence or absence of BSA. The
reaction mixture was incubated either at 37, 60 or 65°C
according to the enzymes used and following the
manufacturer's recommendations. Five µl of the digested-
PCR product were mixed with 5 µl of 5× TBE and 10 µl of
SSCP-loading dye (95% formamide, 0.05% bromophenol
A. Schematic illustration of PKD1 mRNA, long RT-PCR product, and nine overlapping nested-PCR fragments (SI 1–SI 9) used  for the MRF-SSCP analysis Figure 1
A. Schematic illustration of PKD1 mRNA, long RT-PCR product, and nine overlapping nested-PCR fragments 
(SI 1–SI 9) used for the MRF-SSCP analysis. B. Maps of the regions in PKD1 amplified by long-range PCR and 
nested-PCR. 
A. Maps of long RT-PCR and 9 overlapping nested PCRs in PKD1 mRNA
reiterated area unique area
5’ 3’ 10 25 18 15 1 5 36
TH1F/ TH1B (13,634 bp)
SI 4
1,473 bp
SI 2
1,678 bp
SI 6
1,506 bp
SI 8
1,539 bp
1,650 bp
SI 9 SI 3
1,575 bp
SI 5
1,663 bp
SI 7
1,518 bp
SI 1
1,554 bp
46
Ex29 Ex30 Ex15
SI8L
SI7B
SI4.2F SI4.2B
B. Maps of long-range PCR amplification of PKD1 DNA
486 bp 336 bpBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
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blue, 0.05% xylene cyanol, 20 mM EDTA and 10 mM
NaOH). The total mixture was heat-denatured at 95°C for
10 min before loading onto the vertical electrophoresis set
(size: 17 × 15 × 0.8 cm3) of 10% polyacrylamide gel con-
taining 5% glycerol. The electrophoresis was run at a con-
stant current (20 mA) and room temperature for 4–7 h;
the running time was longer for a larger size of the
digested fragments. DNA fragments on the gel were
stained with silver nitrate [23]. After that, the gel was
placed between two sheets of cellophane, left at room
temperature to dry, and kept as a record.
The fragment with mobility shift was amplified with a
newly designed pair of primers. The PCR product was
purified and subjected to a direct sequencing using ABI
PRISM™ BigDye™ Terminator Cycle Sequencing Ready
Reaction Kit and ABI PRISM 310 Automated DNA
Sequencer (PE Applied Biosystems, Foster City, CA, USA).
Genomic DNA analysis
A long-range PCR (LR-PCR) was performed to amplify
genomic DNA in the PKD1 region covering the nucleotide
positions 26340–44438 (18,099 bp). The amplified prod-
uct was then used as template for nested-PCRs (Figure
1B). The primers used for nested-PCRs are listed in Table
1. The methods for LR-PCR and nested-PCR have been
previously described [19]. Briefly, the reaction was per-
formed in a total volume of 25-µl containing 2 µl of the
diluted LR-PCR product, 400 nM of each primer, 200 µM
dNTP mixture, 10 mM Tris-HCl (pH 8.3), 50 mM KCl,
1.25 unit AmpliTaqGold™ (PE Applied Biosystems) or
IMMOLASE™ DNA polymerase (Bioline USA Inc.), 10%
DMSO, and an optimal concentration of MgCl2. The
nested-PCR product was purified for DNA sequencing to
confirm the nucleotide change observed in the PKD1
cDNA.
Once the mutation was identified, a simple detection
method was developed for direct mutation and segrega-
tion analysis in the affected family. In addition, the muta-
tion was examined in 56 DNA samples from unrelated
normal individuals (112 chromosomes). The disease-
causing mutation should not be observed in these normal
DNA samples.
Results
Of ten families studied, ADPKD was found to be PKD1-
linked or probable PKD1-linked by linkage (haplotype)
analysis using 5 polymorphic markers in the PKD1 region
on chromosome 16p in eight families. The results of
haplotype analysis in two families were inconclusive
because of small number of family members.
The RNA samples from the probands of these ten families
were analyzed by the long RT-PCR and nested-PCR meth-
ods. The result showed an about 200 bp shorter nested-
PCR fragment (SI 6) of PKD1 cDNA from the proband (II-
3) of family PK066, indicating an abnormal PKD1-mRNA
splicing. No abnormality in size was, however, observed
for all nested-PCR fragments of PKD1  cDNA from the
other probands; they were then further analyzed by the
MRF-SSCP method. A nonsense mutation and small dele-
Table 2: MRF-SSCP for mutation analysis of the full-length PKD1 cDNA
PCR Fragment
 from PKD1-cDNA
Size (bp) before
 endonuclease digestion
Restriction
 endonuclease used
Restriction fragment length
 (bp) in MRF-SSCP (5' > 3')
SI 1 1,554 Pvu II+Xcm I+Ava II 209, 318, 99, 249, 294, 385
Afl III+Sac I+Ava II 209, 282, 384, 238, 312, 129
SI 2 1,678 Pvu II+Hinf I 429, 93, 366, 277, 295, 218
Sma I+Bgl I 108, 245, 292, 605, 123, 306
SI 3 1,575 Bgl I+Hinf I 233, 81, 424, 198, 325, 202, 112
Taq I 429, 215, 187, 243, 501
SI 4 1,473 Bgl I+Hha I 131, 159, 96, 380, 108, 476, 123
Ava II 178, 252, 475, 204, 253, 111
SI 5 1,663 Sau3A I+Bgl I 127, 387, 377, 188, 226, 169, 189
Ava II+Bgl I 116, 324, 423, 216, 141, 85, 358
SI 6 1,506 Ava II+Bgl I 173, 307, 294, 402, 187, 143
BstU I+BstE II 313, 344, 265, 190, 70, 239, 85
SI 7 1,518 BstU I+Hinf I 112, 287, 424, 389, 201, 105
Ava II+Hinf I 197, 202, 398, 315, 192, 109, 105
SI 8 1,539 Pvu II+Pst I+BstE II 337, 199, 233, 505, 218, 185
Taq I+Bgl I 190, 141, 222, 344, 474, 98, 208
SI 9 1,650 Pvu II 190, 351, 81, 180, 453, 135, 12, 248
Taq I+Bgl I 288, 318, 197, 529, 84, 234BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
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tions causing either frameshift or inframe translations
were identified in the probands of four families. The
details of mutation identified in the five probands and
their families are summarized in Table 3 and described
below.
Splicing defect
The proband (II-3) of family PK066 was the only one in
this family who had the disease with chronic renal failure
at the age of 54 years. His father died from coronary heart
disease at the age of 70 years and his mother was still
healthy at the age of 81 years. It was possible that the hap-
lotype carrying defective PKD1 in the patient might be
inherited from his father (data not shown). As it seems
that the father did not have the disease, a de novo PKD1
mutation in this family was suspected. The analysis of
nested-PCR fragments of PKD1 cDNA from the proband
(II-3) of this family showed a possible deletion of about
200 bp in one fragment (SI 6), which was amplified by
SI6F/SI6R primers (in the region between the nucleotides
7400 and 8905), in one allele. The location of possible
deletion site was examined by restriction endonuclease
mapping on the nested-PCR fragment (data not shown)
and by amplification with additional pair of primers
(SI6.1F/SI6.1B), covering between the nucleotides 7657
and 7978 in the region of exons 18–20, for direct sequenc-
ing. The results showed that an entire sequence of exon 19
was missing from the deleted nested-PCR fragment (Fig-
ure 2A). Further analysis of genomic DNA of PKD1
revealed a novel 31-bp deletion in the region between the
nucleotides 33184–33214 (g.33184_33214del31),
involving the last two nucleotides of exon 19 and twenty-
nine nucleotides in the first part of intron 19, causing
skipping of all sequence of exon 19 (Figure 2A and 2B).
Direct detection of this 31-bp deletion in genomic DNA
samples of the family members could be conducted by
LR-PCR of PKD1 and nested PCR using the pair of SI6.1F/
SI6.1B primers. The result showed that only the proband
carried this novel deletion; none of other six family mem-
bers including the patient's mother had the mutation;
thus, it is likely to be a de novo PKD1 mutation (Figure
2C).
Nonsense mutation
In family PK031, the propositus (I-1) was 55 years old
who had ADPKD at 43 years. His son and daughter also
had multiple renal cysts; however, other 55 members in
the family were not affected by this disease, indicating that
the propositus had a de novo PKD1 mutation that was
inherited to his son and daughter. The MRF-SSCP analysis
of nested-PCR fragment amplified with SI4F/SI4B primers
(fragment SI 4) from PKD1 cDNA of the proband (I-1) of
the family PK031 showed mobility shifts of restriction
fragments digested with Bgl I + Hha I and also with Ava II
(Figure 3A). These were also confirmed by the SSCP anal-
ysis of individual restriction fragments isolated from aga-
rose gels before the analysis (data not shown). The
mobility shifts occurred within the restriction fragments
with the sizes of 476 and 253 bp when digested with Bgl I
+ Hha I and with Ava II, respectively (Figure 3A), corre-
sponding to nucleotides between the positions 5670 and
Table 3: PKD1 mutations in Thai families identified by our group
Family Mutation Location RNA Splicing Defect 
(experimentally 
determined)
Effect on Polycystin-1 
(theoretically deduced)
Reference
PK015a IVS13-2A>T IVS13 Del the first 74 nt of 
exon 14
FS at 1055 (PKD IV-
terminal deletion)
Thongnoppakhun et al., 2000 
[19]
PK039a c.5225_5226delAG 
(g.29124_29125delAG)
Exon 15 - FS at 1672 (PKD XI – 
terminal deletion)
This study, Watnick et al., 
1999[24], Rossetti et al., 2002 
[15]
PK031a,b Q1828X (c.5693C>T) Exon 15 - Stop at 1828 (PKD XIII-
terminal deletion)
This study, Rossetti et al., 
2002 [15]
PK066b g.33184_33214del31 
(31bpE19I19-2 to E19I19+29 
or c.7913_7914+29del31)
Ex19-IVS19 Exon 19 skipping FS at 2498 (REJ module-
terminal deletion)
This study (Novel)
PK069a c.9451_9452delAT 
(g.39376_39377delAT)
Exon 26 - FS at 3082 (TM 1-terminal 
deletion)
This study (Novel)
PK002a L3287del 
(c.10070_10072delCTC or 
g.41669_41671delCTC)
Exon 29 - Inframe deletion of L3287 
(TM 2)
This study (Novel)
PK009a IVS43+14del20 IVS43 Exon 43 skipping Inframe deletion of 3904–
4001 (TM 7–9)
Rungroj et al., 2001 [20]
a Segregation of mutation with disease phenotype b De novo mutation is likely. Reference sequences for DNA and mRNA of PKD1 are GenBank 
Accession No. L39891 and L33243, respectively.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
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5911 of PKD1 cDNA. The sequence in this region was
selectively amplified by a new pair of primers (SI4.1F/
SI4.1B) for sequencing analysis. A single nucleotide sub-
stitution (c.5693C>T) resulting in a nonsense mutation
where a codon for glutamine (CAG) was changed to a stop
codon (TAG) at the position 1828 (Q1828X) in exon 15
of PKD1 was observed (Figure 3B). The mutation with the
nucleotide substitution was confirmed by sequencing
analysis of the PKD1 gene (g.29591C>T). This mutation
abolishes a restriction site of Pvu II endonuclease.
Mutation segregation study by Pvu  II digestion in the
PK031 family demonstrated that three affected members
(I-1, II-1, and II-2) carried this mutation while one non-
affected member (I-2) did not (Figure 3C and 3D).
Frameshift mutations
In family 039, the propositus (I-2) had polycystic kidney
disease at the age of 48 years and died of renal failure one
year later. The patient's sister (I-1) and her daughter (II-1)
were diagnosed as having the disease at 55 and 38 years,
respectively. Two (I-1 and I-2) out of three affected per-
sons in this family exhibited renal stone. The patient's sis-
Novel PKD1-splicing defect identified in family PK066 Figure 2
Novel PKD1-splicing defect identified in family PK066. A. Diagram showing splicing defect resulted from a 
deletion of 31 bp in PKD1. The deletion of 31 bp (g.33184_33214del31) involves the end of exon 19, splice-donor site and a 
part of intron 19, resulting in exon 19 skipping in the PKD1-RNA transcripts. B. Direct sequencing analysis of PKD1-
genomic DNA from the proband. The sequencing result shows the 31-nucleotide deletion including the two last nucle-
otides in exon 19 and the first twenty-nine nucleotides in adjacent intron 19 (g.33184_33214del31) as compared with the 
sequence of HUMPKD1GEN, GenBank Accession No. L39891. C. Direct detection of the 31-bp deletion 
(g.33184_33214del31) in the family PK066. The detection of 31-bp deletion (g.33184_33214del31) in members of the 
family PK066 was directly performed by genomic DNA amplification. Only the proband (II-3) in this family carries the deletion. 
M represents 100 bp ladder-DNA markers.
31-bp deleted region
Deletion of 31 bp resulting in exon 19 skipping
(g.33184_33214del31)
Exon 18
Exon 18 19
20
Exon 18
Exon 18
19
19
20
20
Normal
exon 19 skipping
20
A
1
+ strand CACTCGTCCACCGTCAGACAACTCCCGCT
- strand
nt. 33214
IVS19 Exon19
nt. 33184
31 deleted bases
5’-AGGTGAGCCAGGCCGTGGGAGGGCGCCCCCG-3’
Exon19 IVS19
B
480 bp
I
II
III
M    I-1  II-1  III-1 III-2 II-2  II-3 III-3
C
2
2 1 3
2 1 3
Family PK066
Heteroduplex
DNA
Deleted
fragmentBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
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Nonsense mutation (Q1828X) identified in family PK031 Figure 3
Nonsense mutation (Q1828X) identified in family PK031. A. MRF-SSCP analysis in SI 4 fragment from the 
patient of family PK031. The restriction maps of Bgl I + Hha I and Ava II digestions of SI 4 fragment (upper). The dotted 
square area indicates the region with mobility shifts in the MRF-SSCP analysis of SI 4 fragment from the patient. The SSCP pat-
terns (lower) of SI 4 fragment digested with Bgl I + Hha I (left) and Ava II (right) show mobility shifts of single-stranded DNAs 
(pointed) in the patient's sample (P) compared with that of normal control (N). Double-stranded DNA fragment-size markers 
(ds) were included for each set. The mobility shifts were observed in the fragments with the sizes of 476 bp in the first set and 
253 bp in the second one. The two fragments were located in the same region within the positions 5670–5911. B. Direct 
sequencing analysis of PKD1-cDNA from the patient of family PK031. The sequencing profile shows a nucleotide sub-
stitution (c.5693C>T), resulting in a nonsense mutation; CAG (glutamine) was changed to TAG (stop) at codon 1828 
(Q1828X).C. Restriction map of RFLP analysis for g.29591C>T (Q1828X) in PKD1-genomic DNA. Four DNA frag-
ments with the sizes of 117, 134, 91 and 30 bp are obtained from the normal allele, whereas only 3 fragments with the sizes of 
251, 91 and 30 bp are generated from the mutant allele carrying the g.29591C>T mutation because of the loss of a Pvu II rec-
ognition site at the position 29593. D. Results of direct detection for g.29591C>T (or Q1828X) mutation by Pvu II 
digestion in members of the family PK031. The appearance of 251-bp fragment in I-1, II-1, and II-2 indicates the presence 
of Q1828X mutation. The mother (I-2) did not have the 251-bp fragment; thus, she did not carry the mutation. N is normal 
control sample digested with the same enzyme.
Pvu II digestion
Wild-type
Q1828X
SI4.1F/SI4.1B (372 bp)
134 117
30
30 91
91 251
B
C
c.5693C>T, Q1828X
1824   1825   1826   1827    1828         Codon
Pro     Phe Tryp Gly STOP       Amino acid
T
117
91
251
134
bp
N   I-1   I-2   II-1   II-2
I
II
Family PK031
1
D
ds N P
476
380
159
131,123
108
Ava II
Bgl I + Hha I 131 159 96 476 108 380 123
178 475 252 204 253 111
96
MRF-SSCP analysis in PK031: SI-4 fragment (1473 bp, nt. 4562-6034) 
A
Bgl I + Hha I
475
253,252
204
178
111
ds NP
Ava II
2
2 1BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
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ter (I-1) also had severe hypertension causing serious
headache but no intracranial aneurysm was detected by
magnetic resonance angiography. The MRF-SSCP analysis
of nested-PCR fragments amplified with SI4F/SI4B prim-
ers (SI 4) from PKD1 cDNA of an affected person (I-1) in
this family revealed mobility shifts of restriction frag-
ments digested with either Ava II or Bgl I + Hha I (Figure
4A). A deletion of AG di-nucleotides
(c.5225_5226delAG) at codon 1672, resulting in a
frameshift translation starting from this codon (Figure
4B) was finally identified. The di-nucleotide deletion was
confirmed by sequencing of genomic DNA in exon 15 of
PKD1 (g.29124_29125delAG). This mutation has been
previously reported in many Caucasian families [15,24]
and its correlation to cerebral aneurysm phenotype was
questioned [24]. This mutation abolishes an Eco0109 I
restriction site. Mutation segregation analysis by Eco0109
I digestion of amplified genomic DNA samples in the
family PK039 showed that three affected members (I-1, I-
2, and II-1) carried the mutation while a non-affected per-
son (II-2) did not (Figure 4C).
The proband (II-I) of the family PK069 attended our renal
clinics with the problem of end-stage chronic kidney dis-
ease at the age of 42 years. She was found to have poly-
cystic kidney disease and since then she commenced on
hemodialysis. Three of her siblings (II-2, II-3, and II-5)
also had the disease but with normal renal function. Her
father was still healthy at the age of 81 years. Her mother
died of cervical cancer at the age of 38 years. PKD might
be inherited from her mother. Mobility shifts were found
in the MRF-SSCP analysis of SI 7 fragment from PKD1
cDNA of the proband (II-1) (Figure 4D). The final
sequence analysis in both cDNA and PKD1-specific DNA
indicated a deletion of AT at codons 3080 and 3081
(c.9451_9452delAT or g.39376_39377delAT), resulting
in a frameshift translation starting from codon 3082 (Fig-
ure 4E). This mutation abolishes an AfI III restriction site.
Analysis of the mutation by Afl III digestion in the availa-
ble members of family PK069 demonstrated that all four
affected persons (II-1, II-2, II-3, and II-5) carried the muta-
tion while two unaffected members (I-1 and II-4) did not
(Figure 4F).
In-frame deletion
The propositus (II-2) of family PK002 was diagnosed as
having ADPKD at 24 years old. He developed ESRD at the
age of 50 years old and has been commenced on
hemodialysis at frequency of three times a week since
then. He is now aged 56 years old. His father (I-1) experi-
enced a long-standing hypertension and died at the age of
52 years. His elder sister (II-1) manifested polycystic kid-
ney disease at the age of 37 years. She is now aged 60,
being suffered from chronic renal failure (serum
creatinine level 6 mg/dl). Further ultrasound work-up
revealed renal cysts in 3 out of 7 members in the subse-
quent generation. Obvious mobility shifts in the MRF-
SSCP analysis were observed in SI-7 PCR product from
PKD1 cDNA of an affected member (II-1) of this family
when compared with the normal counterparts (Figure
5A). Direct sequencing revealed an in-frame deletion of
CTC from c.10070_10072 (or g.41669_41671), resulting
in a single amino acid (leucine) deletion at the position
3287 (L3287del) (Figure 5B).
Sequence alignments of polycystin-1 among distant spe-
cies from human through worm (Caenorhabditis elegans)
reveal that L3287 is highly conserved (Figure 5C). In addi-
tion, screening in our control set of 112 normal chromo-
somes did not show the L3287del in PKD1. The L3287del
mutation could directly be detected by the heteroduplex
analysis of the amplified PKD1-specific fragment. The
presence of L3287del mutation in five affected members
(II-1, II-2, III-2, III-4, and III-6) but its absence in eight
unaffected members of PK002 family were demonstrated
(Figure 5D).
Single nucleotide polymorphisms
Using the MRF-SSCP analysis for screening the entire
PKD1-cDNA sequence, we found a considerable number
of mobility shifts of single-stranded DNA fragments.
Many of these mobility shifts were not taken for further
analysis because they were common in several patients as
well as in normal control individuals. Thus, they were
likely to be common single nucleotide polymorphisms
(SNPs). In the cases that the mobility shifts were unique
in the patients or in families possible to be mutations,
they were then subjected to the detailed analysis. How-
ever, instead of being disease mutations, several SNPs in
the PKD1 gene were identified as presented in Table 4.
Discussion
We have developed a long RT-PCR method for amplifica-
tion and isolation of the entire PKD1-coding sequence
from its RNA transcripts prepared from peripheral blood
lymphocytes, avoiding the interference from transcripts of
PKD1-homologous genes [18]. This amplified full-length
PKD1 cDNA is a useful material for mutation analysis.
Since the amplified product was originated from PKD1
mRNA, abnormal transcripts resulted from mutations
causing defective RNA splicing can directly be analyzed
without the requirement for additional expression experi-
ment. In addition, this amplified product can also be used
for analysis of other PKD1  mutations. An LR-PCR for
genomic-DNA amplification of 18 kb covering exons 13–
34 region of PKD1 has also been developed for confirma-
tory mutation analysis in genomic DNA [19]. In our pre-
vious works, we have demonstrated the use of long RT-
PCR and nested-PCR procedure and LR-PCR method for
characterization of two PKD1 mutations causing splicingBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
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Frameshift deletions found in families PK039 (A-C) and PK069 (D-F) Figure 4
Frameshift deletions found in families PK039 (A-C) and PK069 (D-F). A, D. MRF-SSCP analyses of SI-4 and SI-
7 fragments from the patients of families PK039 and PK069, respectively. The maps of restriction fragments 
obtained from digestions of PCR fragments by sets of endonucleases in two families are shown (upper). The MRF-SSCP analy-
ses (lower) of the patients (P) from both families show mobility shifts of single-stranded DNAs (pointed) when compared with 
those of normal controls (N). These fragments are located in the dotted box of the upper map. B, E. Sequencing analyses 
of PKD1-cDNA from the two patients. The sequencing profiles of both families show different types of two nucleotide 
deletions (c. 5225_5226delAG and c.9451_9452delAT), resulting in frameshift translation, as compared with the normal 
sequence. C, F. Direct detection of the two deletions (g.29124_29125delAG and g.39376_39377delAT) in mem-
bers of the families PK039 and PK069, respectively. The di-nucleotide deletions in PKD1 genomic-DNA in members of 
both families were detected by restriction analyses. The two mutations abolish recognition sites of Eco0109 I and Afl III, respec-
tively. The presence of larger fragment in each case indicates the existence of mutation.
MRF-SSCP analysis in PK069:
SI-7 fragment (1518 bp, nt 8709-10226)
BstUI  +  Hinf I I
112 287 424 201 105 389
A
NP
424
389
112
201
287
105
ds NP
475
253,252
204
178
111
MRF-SSCP analysis in PK039:
SI-4 fragment (1473 bp, nt 4562-6034)
178 475 252 204
Ava II
253 111
D
B
Mutant AGGGACGGGCCCGGCCCTGGCCGG
Deleted nucleotide 5225-5226 in mutant sequence
Codon 1670   1671   1672   1673   1674   1675  1676  1677
AGGGACAGGGGCCCGGCCCTGGCC
R     D      G     P      G      P    G      R
Normal
R      D     R     G      P      A     L     A
E
Mutant CTGACGTGCTGTGTGCCTGGTGAC
Deleted nucleotide 9451-9452 in mutant sequence
Codon 3079   3080   3081  3082   3083  3084   3085   3086
CTGACATGTGCTGTGTGCCTGGTG
L      T      C     C      V      P     G     D
Normal
L      T      C     A      V     C      L     V
F
631
330
301
67
1000
500
100
bp
Afl III digestion SI7.2F/SI7.2B (698 bp)
301
67 631
330 67 Wild-type
c.9451delAT
M   I-1  II-1  II-2 II-3  II-4  II-5
Family PK069
I
II
1 2 3 4
1
5
2
486 bp
400 bp
86 bp
Eco0109 I digestion of SI4.2F/SI4.2B (486 bp)
C
486
400 86 Wild-type
c.5225delAG
N      I-1    II-1   II-2    I-2 
Family PK039
I
II
1 2
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Novel in-frame deletion (L3287del) identified in family PK002 Figure 5
Novel in-frame deletion (L3287del) identified in family PK002. A. MRF-SSCP analysis of SI 7 fragment of the 
patient. The restriction map shows multiple fragment sizes obtained from digestions with two sets of restriction endonucle-
ases (upper). The dotted square indicates the region with mobility shifts in the digested SI 7 fragment from the patient of family 
PK002. The SSCP patterns generated from digestions with two sets of enzymes (lower) and mobility shifts of single-stranded 
DNA (pointed) are shown. B. Direct sequencing analysis of PKD1-cDNA from the patient. The sequencing profile 
shows a deletion of three nucleotides (CTC; c.10070_10072del), resulting in an in-frame mutation. The CTC deletion causes 
missing of leucine at position 3287 in polycystin-1 (L3287del). C. Multiple sequence alignment of polycystin-1 from 
human, dog, rat, mouse, pufferfish and worm by using ClustalW program [33]. Amino acid residues around L3287 
are shown. L3287 is highly conserved among distant species in which only in C. elegans that the residue is replaced by isoleu-
cine, which is in the same group of amino acid. D. Direct detection for L3287del in members of the family PK002 by 
SSCP analysis. The L3287del could be detected by the presence of heteroduplex DNAs on the SSCP analysis. In the family 
PK002, five members carried the mutation while nine did not. M is standard DNA markers and ds is double-stranded DNA of 
a normal control.
B
D
C
ds N P
MRF-SSCP analysis in PK002: SI-7 fragment (1518 bp, nt. 8709-10226) 
A
BstUI  +  HinfI
398
315
202
197
109
ds NP
Ava II + HinfI
192
105
424
389
201
112
105
287
BstUI  +  HinfI
Ava II + HinfI
112 287 424 389 201 105
197 202 315 192 109 105 398
Family PK002
M    ds I-2 II-1  III-1  IV-1  III-2  III-3 III-4   II-2   II-3   III-5 III-6  III-7  II-4   II-5
336 bp
I
II
III
IV
12
2 1
1
1
2
3
4 5 6 7
3
3
45
c.10070_10072delCTC ( L3287del)
Codon 3285   3286   3287 3288   3289    3290
GTTCTCCTCATCTGCCTC
GTTCTCATCTGCCTCTTC
Normal
Mutant
V      L      L I       C      L
Polycystin-1 alignment among species
NP_000287.2 (Human)
AAM45378.1 (Dog)
AAG33986.1 (Rat)
NP_038658.1 (Mouse)
AAB86683.1 (Pufferfish)
NP_496184.1 (Worm)
L3287
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defects in two Thai families [19,20]. The advantage of
simultaneous characterization of abnormal RNA splicing
with the mutation has also been demonstrated in a recent
work by Burtey et al. [25] who developed a method for
PKD1 mutation screening by RT-PCR and reported three
splicing defects out of six mutations identified. Unlike our
RT-PCR and nested-PCR method that require only 10 PCR
reactions per one sample, the recently reported method
[25] needs as many as 57 PCR reactions per one sample.
Another advantage of the method that we developed is
that it uses reagents and equipments available in general
molecular genetic laboratory. In addition, the mutation
screening method can be modified to increase efficiency
and to be suitable for each laboratory. However, several
disadvantages are present in analysis of PKD1 transcript
including difficulty in sample handling and storage
because of its unstable nature making it unpopular for
routine service laboratory, complicated experimental pro-
cedure in cDNA synthesis, and presence of false-positive
results due to contamination of atypical illegitimate prod-
ucts which sometimes puzzle interpretation of result and
make it necessary to analyze of PKD1-genomic DNA for
confirmation of mutation.
In this study, we have further applied the developed long
RT-PCR followed by nested PCR and long-range genomic-
DNA amplification for analysis of mutation in the reiter-
ated region of PKD1 in Thai families with ADPKD. The
MRF-SSCP technique has been developed and
preliminarily used for screening other types of mutations.
This method is able to screen mutation in a long cDNA
fragment (>1 kb) amplified by nested PCR and it is feasi-
ble to use for mutation screening in the entire sequence of
PKD1 cDNA, reducing the numbers of PCR reactions and
SSCP gels required for the analysis. In the application of
long RT-PCR and mutation screening by MRF-SSCP in our
study, we could detect PKD1 mutations in 5 out of 10
families (50%). The limitation of detection rate may be
due to low sensitivity of SSCP for mutation screening in
long cDNA fragments (>300 bp) usually present after the
digestion of PCR products with restriction enzymes and
also probably due to the use of only single SSCP condi-
tion. However, this detection rate is comparable to that of
protein-truncation test (PTT) which is about 52% [26,27]
although it is lower than that of DGGE [28-30] and
DHPLC [15] which are about 60% and 70%, respectively.
In the MRF-SSCP analysis, false-positive mobility shifts of
the digested-cDNA fragments were found to be about
10%, which could be mainly eliminated by repeating the
screening experiment or performing the analysis in more
than one affected members in the same family. Although
PTT method can screen for a relatively large cDNA frag-
ments (~2 kb) and the detected alterations are almost all
pathogenic mutations, its major disadvantage is that
missense mutations, which are a significant source of
PKD1 mutation [27] or small in-frame changes are not
detected. Thus, it may not be an ideal screening method
for detection of all types of PKD1 mutations. DGGE and
DHPLC are the methods of choice provided that the
equipments are available and the detection conditions are
well optimized. Direct sequencing of the entire PKD1
gene is however very expensive if mutation screening is
not initially performed and it may not be appropriate for
such a large gene as PKD1.
Using the previously reported and this newly developed
method, we have identified three novel (splicing,
frameshift and in-frame) mutations and two known
(nonsense and frameshift) alterations in five Thai families
with ADPKD (Table 3 and Figure 6). Two of these (splic-
ing and nonsense) changes are possibly de novo muta-
tions. All these mutations located in the reiterated region
which were confirmed by analyses of PKD1-genomic DNA
using LR-PCR method and direct sequencing. A novel
splicing defect that was identified in family PK066 is
g.33184_33214del31 which resulted in exon 19 skipping,
most likely because of the deletion of splice-donor site of
intron 19. Missing of exon 19 sequence in PKD1 mRNA
will cause a frameshift in polycystin-1 translation. The
predicted protein would have a novel 50 amino-acid
sequence after the residue 2497 and would terminate at
the position 2548. Thus, the mutant protein would lack
almost half of polycystin-1 in its C-terminus starting from
the REJ module. The second novel mutation is a
frameshift deletion (c.9451_9452delAT) identified in
family PK069, resulting in a frameshift translation after
codon 3081. Novel 95 amino acids would be observed in
Table 4: PKD1 polymorphisms detected in Thai population
Polymorphism Location Nucleotide change Amino acid change Frequency (%) Detection method Presence in HGsa
c.10078C>T Exon 29 g.41677C>T C3289C 16.4 (18/110) BsmA I (+) Yes
c.10120C>T Exon 29 g.41719C>T G3303G 4.5 (5/110) Hph I (+) Yes
c.10158G>A Exon 30 g.41847G>A S3316N 15.5 (17/110) Bsp1286 I (-) Yes
c.10318C>T Exon 31 g.43666C>T S3369S 0.9 (1/114) Pvu II (-) No
IVS41+20C>T IVS41 g.49833C>T - 1.0 (4/400) ASAb No
aAnalyzed from multiple alignment of PKD1-genomic DNA with 6 homologous genes or pseudogenes [17,34]. bAllele specific amplification.BMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
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this mutant protein before premature termination at the
position 3177, truncating all the C-terminus of polycys-
tin-1 beginning from TM 1. The third novel mutation
identified in family PK002 is an in-frame deletion
(L3287del) affecting a highly conserved residue in TM2
domain of polycystin-1. The proband in the family had
ESRD and the youngest affected member (III-6) was diag-
nosed at 7 years old (Figure 5). The frameshift mutation
due to di-nucleotide deletion in exon 15
(c.5225_5226delAG) found in family PK039 has been
previously reported in several unrelated Caucasian fami-
lies [15,24]. The di-nucleotide deletion causes frameshift
translation beginning at codon 1672, introducing novel
97 amino acids and premature termination at codon
1768. This mutation might associate with cerebral
aneurysm [24] but this association was not seen in this
reported Thai family. Instead, it is suspected to correlate to
ESRD as observed in the proband. A nonsense (Q1828X)
mutation in exon 15 identified in family PK031 has
recently been reported in a European family (P 293) in
which another nonsense mutation (S2164X) was concur-
rently identified on the same chromosome [15]. This
nonsense (Q1828X) mutation in the Thai family should
occur independently as a de novo event in the patient and
inherited to his son and daughter, since this mutation and
ADPKD were not observed in other 55 members of his
kindred.
PKD1 mutations reported so far in Thai families appear to
be heterogeneous, similar to other ethnic origins world-
wide. However, some degree of clustering of mutations in
the regions encoding the PKD repeats and REJ domain of
polycystin-1 is noticed (Figure 6) [19,20,31,32]. The
mutations that we identified in this and previous studies
[19,20] consisted of splicing, frameshift, in-frame and
nonsense alterations. We have not yet observed missense
mutations which have already been reported in Thai
patients with ADPKD by Phakdeekitcharoen et al. [31,32].
It is possible that our method has a low sensitivity for
detecting missense mutation. However, as several single
nucleotide polymorphisms (SNPs) could be identified
(Table 4), we believe that our method is capable to also
Distribution of PKD1 mutations identified in Thai patients with ADPKD Figure 6
Distribution of PKD1 mutations identified in Thai patients with ADPKD. Diagrams of polycystin-1 (upper) and PKD1 
gene (lower) show domain structures and coding regions for the protein domains, respectively. Seven PKD1 mutations (above 
polycystin-1) were identified by our groups, while the other eighteen (under polycystin-1) were also reported in Thai patients 
by Phakdeekitcharoen et al. [31,32]. Majority of the mutations locate in the regions encoding PKD repeats, REJ and the begin-
ning TM domains.
= Splicing defect
= Deletion          
= Insertion       
= Nonsense mutation        
= Missense mutation
10 25 18 15 1 5 46
P
L
A
T
-
L
H
2
Cytoplasmic
tail
REJ domain PKD repeats 2-16 TM &
Loop
regions
L
R
R
L
e
c
t
i
n
L
D
L
G
P
S
P
K
D
 
r
e
p
e
a
t
 
1
W
S
C
c
.
9
4
5
1
_
9
4
5
2
d
e
l
A
T
g.33184_
33214del31
Q
1
8
2
8
X
I
V
S
1
3
-
2
A
>
T
IVS43+14del20
36
c
.
5
2
2
5
_
5
2
2
6
d
e
l
A
G
L
3
2
8
7
d
e
lBMC Medical Genetics 2004, 5 http://www.biomedcentral.com/1471-2350/5/2
Page 14 of 15
(page number not for citation purposes)
identify this type of mutation. It is likely that no detecta-
ble missense mutation in our study may occur by chance.
No relationship between specific mutation and clinical
manifestations was found from our data, similar to that
observed in many other reports. With our long RT-PCR
and nested PCR and the mutation screening by MRF-SSCP
method or other modifications to increase screening effi-
ciency such as the use of DHPLC [15], we expect to iden-
tify majority of PKD1 mutations, if not all, in our patients
for the benefits of better understanding of pathogenesis of
ADPKD, development of rapid molecular genetic diagno-
sis, and improvement of preventive measure for the com-
plications related to the disease.
Conclusions
This study is the first report using the long RT-PCR
method in combination with MRF-SSCP for mutation
screening of PKD1 cDNA and total five mutations were
identified within the reiterated region. Three mutations
(splicing defect, frameshift alteration and in-frame dele-
tion) are novel. Two mutations (splicing defect and non-
sense change) are possibly de novo.  PKD1  mutations
reported so far in Thai patients with ADPKD are
heterogeneous but mutations in a majority group of
patients are still unknown, requiring further
characterization.
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